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Abstract
Background: In the National Emphysema Treatment Trial (NETT), marked variability in response
to lung volume reduction surgery (LVRS) was observed. We sought to identify genetic differences
which may explain some of this variability.
Methods: In 203 subjects from the NETT Genetics Ancillary Study, four outcome measures were
used to define response to LVRS at six months: modified BODE index, post-bronchodilator FEV1,
maximum work achieved on a cardiopulmonary exercise test, and University of California, San
Diego shortness of breath questionnaire. Sixty-four single nucleotide polymorphisms (SNPs) were
genotyped in five genes previously shown to be associated with chronic obstructive pulmonary
disease susceptibility, exercise capacity, or emphysema distribution.
Results: A SNP upstream from glutathione S-transferase pi (GSTP1; p = 0.003) and a coding SNP
in microsomal epoxide hydrolase (EPHX1; p = 0.02) were each associated with change in BODE
score. These effects appeared to be strongest in patients in the non-upper lobe predominant, low
exercise subgroup. A promoter SNP in EPHX1 was associated with change in BODE score (p =
0.008), with the strongest effects in patients with upper lobe predominant emphysema and low
exercise capacity. One additional SNP in GSTP1  and three additional SNPs in EPHX1  were
associated (p < 0.05) with additional LVRS outcomes. None of these SNP effects were seen in 166
patients randomized to medical therapy.
Conclusion: Genetic variants in GSTP1 and EPHX1, two genes encoding xenobiotic metabolizing
enzymes, were predictive of response to LVRS. These polymorphisms may identify patients most
likely to benefit from LVRS.
Background
The National Emphysema Treatment Trial, a multicenter
randomized trial of lung volume reduction surgery
(LVRS) versus medical management for emphysema,
found that on average, LVRS led to improved functional
status, but not increased survival in patients with emphy-
sema and severe chronic airflow obstruction [1]. How-
ever, substantial variability in response to LVRS was
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observed. Based on pulmonary function testing and
emphysema distribution on chest computed tomography
(CT), a patient population with a high risk of death was
identified [2]. Among non-high risk patients, baseline
exercise capacity and emphysema distribution on chest CT
scans were used to define subgroups with greater or lesser
chances of improvement post-LVRS. Yet these clinical sub-
groups did not fully account for the variable response to
LVRS among NETT participants.
We hypothesized that genetic differences may explain
some of this variability in response to LVRS. To test this
hypothesis, we studied participants in the NETT Genetics
Ancillary Study. We examined the association between
LVRS outcomes and variants in five genes previously
shown to be associated with chronic obstructive pulmo-
nary disease (COPD) susceptibility, exercise capacity, or
emphysema distribution on chest CT [3-7]: glutathione S-
transferase pi (GSTP1), microsomal epoxide hydrolase
(EPHX1), transforming growth factor beta-1 (TGFB1), ser-
pin peptidase inhibitor E2 (SERPINE2) and surfactant,
pulmonary-associated protein B (SFTPB). Though not a
"pharmacogenetic" study in the classic sense of the term –
since the intervention studied is a surgical procedure and
not a pharmacological agent – the present study is the first
to examine genetic associations for response to a specific
therapy for COPD.
Methods
Study Subjects
Study enrollment and phenotype measurements in NETT
have been reported [1,8]. Subjects enrolled in NETT had
severe airflow obstruction (FEV1 ≤ 45% predicted), hyper-
inflation (total lung capacity ≥ 100% predicted), and
bilateral emphysema on high-resolution chest CT. Sub-
jects were excluded if they had major comorbid illnesses,
including significant cardiovascular disease, interstitial
lung disease, or malignancy. Maximal exercise capacity
was determined by incremental cycle ergometry [1]. The
University of California, San Diego, shortness of breath
questionnaire (UCSD SOBQ) was used to quantify dysp-
nea, with higher scores indicating more severe dyspnea
[1,9]. Spirometry was performed according to ATS stand-
ards [1,10]. The BODE (Body mass index, airflow
Obstruction, Dyspnea, Exercise capacity) index is a 10-
point composite score in which higher scores predicted
poorer emphysema outcomes [11]. We modified the
BODE index to include the UCSD SOBQ as the dyspnea
instrument instead of the Medical Research Council dysp-
nea scale, which was not available in NETT [6,12]. The
other components of the BODE index included body
mass index, post-bronchodilator FEV1 (% predicted), and
6-minute walk test distance [11].
In the NETT Genetics Ancillary Study, participants were re-
contacted by the sixteen participating NETT Centers. After
written informed consent, subjects provided a blood sam-
ple for DNA extraction. To limit genetic heterogeneity, the
analysis was limited to non-Hispanic white participants
without severe α1-antitrypsin deficiency; a total of 203
LVRS patients and 166 medically treated patients were
included. The NETT Genetics Ancillary Study was
approved by the institutional review boards at participat-
ing NETT centers.
Genotyping
Single nucleotide polymorphisms (SNPs) were selected in
five genes: GSTP1, EPHX1, TGFB1, SERPINE2 and SFTPB.
We used genotype data from European-Americans (CEU)
in the International HapMap project [13] and in the Seat-
tleSNPs database [14] to select a set of linkage disequilib-
rium (LD)-tagging SNPs for each gene. Pairwise LD-
tagging was implemented in Tagger [15], with a minimum
minor allele frequency of 0.1 and r2 threshold of 0.9. Spe-
cific SNPs previously associated with COPD or related
traits were also included.
The 64 SNPs were genotyped on one of three platforms
(see Additional file 1): allele specific hybridization (Illu-
mina Golden Gate assay, San Diego, CA), the 5' to 3' exo-
nuclease assay (TaqMan, Applied Biosystems, Foster City,
CA) or with unlabeled minisequencing reactions and
mass spectrometry (Sequenom, San Diego, CA).
Statistical Analysis
Four outcome measurements were analyzed: modified
BODE index [11,12], post-bronchodilator FEV1 (liters),
maximum work achieved on a cardiopulmonary exercise
test, and the UCSD SOBQ score [9]. We considered out-
come measurements at six months following randomiza-
tion, in order to allow for recovery from surgery, but to
precede the loss of benefit from LVRS that occurs over
time [16]. LVRS response was defined as the difference
between this measurement and the baseline, recorded fol-
lowing pulmonary rehabilitation, but prior to randomiza-
tion.
Genotype-phenotype correlations were assessed by linear
regression, with adjustment for age, sex, and pack-years of
smoking, assuming additive genetic models by testing for
a linear trend across 0, 1, and 2 copies of the minor allele.
Models for FEV1 and maximum work were additionally
adjusted for height. As a secondary analysis, stratified
analyses were performed in the four subgroups defined in
NETT [1]. Similar models were performed in subjects in
the NETT Genetics Ancillary Study who had been rand-
omized to medical therapy. Analyses were conducted
using SAS version 9.1 (SAS Institute, Cary, NC) or R [17].
LD was calculated using Haploview [18]. Statistical powerRespiratory Research 2007, 8:59 http://respiratory-research.com/content/8/1/59
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was estimated using Quanto [19], assuming additive
genetic models, with a two-sided α = 0.05. Putative tran-
scription factor binding sites were identified with MAP-
PER [20].
Results
Study Subjects
Characteristics of the 203 non-Hispanic white partici-
pants in the NETT Genetics Ancillary Study who under-
went LVRS are shown in Table 1. These subjects resembled
the full cohort of 608 patients randomized to LVRS in
NETT [1]. Outcomes at six months are also shown in
Table 1. On average, participants showed improvement
post-LVRS, with increases in FEV1 and exercise capacity
and decreases in BODE score and dyspnea. However, Fig-
ure 1 demonstrates the variability in response to LVRS
among study participants.
LVRS Response
The genotype frequencies of all 64 SNPs conformed to the
expectation under Hardy-Weinberg Equilibrium (at a
threshold of p < 0.01), except for one SNP in GSTP1,
rs1799811; this SNP was removed from subsequent anal-
yses. The results of the association analyses for the remain-
ing 63 SNPs are highlighted in Table 2. A SNP 5' to GSTP1
and a promoter and a coding SNP in EPHX1 were signifi-
cantly (p < 0.05) associated with change in BODE score;
the promoter SNP in EPHX1  was also associated with
change in UCSD SOBQ score. A SNP 3' to GSTP1 was sig-
nificantly associated with changes in post-bronchodilator
FEV1 and maximum work. An intronic SNP in EPHX1 was
associated with FEV1 change. Two additional SNPs in
EPHX1 (rs1051741 and rs2292558), in strong LD with
each other (r2 = 0.97), were associated with change in
maximum work. The two SNPs in GSTP1 and the pro-
moter SNP in EPHX1 remained significant when a p-value
<0.01 was used to define significance, as an adjustment
for the five genes tested.
One SNP in SERPINE2 and a total of five SNPs in TGFB1
showed trends for association with one or more LVRS
response phenotypes, but none were significant at p <
0.05. None of the SNPs tested in SFTPB were significantly
associated.
Subgroup Analyses
The significant genotype-phenotype associations for SNPs
in GSTP1 and EPHX1 were further evaluated in four clini-
cally-defined subgroups of patients in NETT [1], based on
emphysema distribution and baseline exercise capacity.
Emphysema distribution was categorized as upper lobe
predominant or non-upper lobe predominant, based on
the radiologist's interpretation of the chest CT scan. Low
baseline exercise capacity was defined by sex-specific
thresholds of maximum work achieved on cycle ergom-
Frequency distributions of changes in outcomes at six  months in 203 lung volume reduction surgery patients in the  NETT Genetics Ancillary Study Figure 1
Frequency distributions of changes in outcomes at six 
months in 203 lung volume reduction surgery patients in the 
NETT Genetics Ancillary Study. 
BODE = Body mass index, airflow Obstruction Dyspnea 
Exercise tolerance; FEV1= forced expiratory volume in 1 sec-
ond; CPET = cardiopulmonary exercise test; UCSD SOBQ = 
University of California, San Diego shortness of breath ques-
tionnaire
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Table 1: Characteristics of NETT Genetics Ancillary Study 
subjects who underwent lung volume reduction surgery (LVRS). 
N = 203 unless otherwise noted
Characteristic Mean (SD) or N(%)
Baseline (pre-randomization)
Age, years 67.5 (6.2)
Male sex 123 (60.6%)
Pack-years of smoking 65.2 (29.6)
Upper lobe predominant emphysema 143 (70.4%)
Low exercise capacity 82 (40.4%)
Modified BODE score 4.7 (1.6)
Post-bronchodilator FEV1, liters 0.80 (0.26)
Post-bronchodilator FEV1, % predicted 28.2 (7.5)
Maximum work achieved on CPET, watts 41.8 (21.9)
UCSD shortness of breath questionnaire 58.7 (17.5)
Change at 6 months post-LVRS
Modified BODE score (N = 195) -1.3 (1.7)
Post-bronchodilator FEV1, liters (N = 200) 0.23 (0.26)
Post-bronchodilator FEV1, % predicted (N = 200) 8.9 (9.8)
Maximum work achieved on CPET, watts (N = 198) 6.4 (14.1)
UCSD shortness of breath questionnaire (N = 202) -18.7 (20.7)
BODE = Body mass index, airflow Obstruction, Dyspnea, Exercise 
tolerance;
CPET = cardiopulmonary exercise test; FEV1 = forced expiratory volume in 
1 second;
UCSD = University of California, San DiegoRespiratory Research 2007, 8:59 http://respiratory-research.com/content/8/1/59
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etry (≤ 40 watts for men or ≤ 25 watts for women). Distri-
bution of subjects in each subgroup is as follows: upper
lobe predominant, low exercise capacity 59 (29.1%);
upper lobe predominant, high exercise capacity 84
(41.4%); non-upper lobe predominant, low exercise
capacity 23 (11.3%); non-upper lobe predominant, high
exercise capacity 37 (18.2%). The fourteen patients who
would be defined as high-risk [2] were not excluded from
the subgroup analysis, due to the already limited number
of subjects in the subgroups.
Because of the small sample sizes, only SNPs that were sig-
nificantly associated (p < 0.05) with a specific phenotype
in all subjects were examined in an exploratory subgroup
analysis. Table 3 shows the subgroup analysis for SNPs in
GSTP1 that were significantly associated with at least one
trait in all subjects. The minor allele of rs612020, located
5' to the GSTP1 transcript, was associated with a reduction
in BODE score (signifying clinical improvement) in all
subjects. This SNP was associated with greater improve-
ment in patients with low exercise capacity, with both
upper lobe predominant and non-upper lobe predomi-
nant emphysema (Figure 2). In the non-upper predomi-
nant, low exercise capacity subgroup, the effect of the SNP
was more than twice that in all subjects; the p-value was
the same, despite the marked reduction in sample size. In
all subjects, the minor allele at rs11227884, 3' to the
GSTP1 gene, was associated with improvement in FEV1
and maximum work. The effect of the SNP on maximum
work was stronger in the upper lobe predominant, low
exercise capacity subgroup, though that association did
not reach statistical significance.
A similar stratified analysis for SNPs in EPHX1 is detailed
in Table 4. A promoter SNP in EPHX1, rs375658, was
associated with decreased BODE index and decreased
USCD SOBQ score, both representing clinical improve-
ment, in all subjects. These effects were stronger in the
upper lobe predominant, low exercise capacity subgroup
(Figure 3). An intronic SNP in EPHX1, rs1877724, was
associated with a slight worsening in FEV1, again with
stronger effects in upper lobe predominant, low exercise
capacity patients. The His139Arg coding variant
(rs2234922) was associated with worsening BODE score
and a decrease in exercise capacity, with the effects on
BODE score stronger in the non-upper lobe predominant,
Table 2: Genetic associations with lung volume reduction surgery response at 6 months. Associations with p-values < 0.1 are shown. 
All analyses are adjusted for age, sex, and pack-years of smoking. Analyses of FEV1 and maximum work are also adjusted for height
Gene (total SNPs) SNP Minor allele frequency BODE score Post-BD FEV1 Maximum work USCD SOBQ score
GSTP1 (7) rs612020
5' genomic
0.083 0.003
rs11227884
3' genomic
0.073 0.003 0.02
SFTPB (5) --*
SERPINE2 (22) rs6436449 intron 0.17 0.07 0.09
EPHX1 (19) rs3753658 promoter 0.10 0.008 0.02
rs1877724 intron 0.26 0.04
rs2234922 His139Arg 0.19 0.02 0.05
rs1051741 exon, synon. 0.11 0.09 0.01
rs360063
3' genomic
0.38 0.07 0.05
rs2292558
3' genomic
0.11 0.09 0.03
rs1009668
3' genomic
0.10 0.08
TGFB1 (11) rs2241712 promoter 0.32 0.07
rs8110090 intron 0.05 0.09
rs8179181 intron 0.26 0.06
rs12981053
3' genomic
0.15 0.06
rs12980942
3' genomic
0.15 0.05
SNP = single nucleotide polymorphism; BD = bronchodilator; FEV1 = forced expiratory volume in 1 second; BODE = Body mass index, airflow 
Obstruction, Dyspnea, Exercise tolerance; UCSD SOBQ = University of California, San Diego shortness of breath questionnaire
*No SNPs with p-value < 0.1Respiratory Research 2007, 8:59 http://respiratory-research.com/content/8/1/59
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low exercise capacity subgroup. Two additional SNPs in
EPHX1 showed an association with worsening exercise
capacity. The effects were stronger in both non-upper lobe
predominant subgroups, though not statistically signifi-
cant.
Post-Operative Complications
To explore the possibility that the significant SNPs were
affecting LVRS response through effects on post-operative
complications, we re-analyzed the two significant (p <
0.05) SNPs in GSTP1 and five significant SNPs in EPHX1
after excluding fourteen patients with a post-LVRS hospi-
tal length of stay greater than thirty days. The effect esti-
mates and p-values for the two GSTP1  SNPs were not
substantially changed. In EPHX1, the promoter SNP
(rs3753658) was associated with greater improvement
(BODE β = -1.0, p = 0.003; UCSD SOBQ β = -10.5, p =
0.004). The His139Arg SNP was less detrimental (BODE
β = 0.4, p = 0.1; maximum work β = -2.9, p = 0.1), though
this effect was not statistically significant. The effects of
the other three SNPs in EPHX1 were unchanged.
Medical Arm
In order to ensure that the SNP effects seen in the LVRS
patients were not merely reflective of the natural history of
severe emphysema, we examined 166 patients from the
NETT Genetics Ancillary Study who had been randomized
to medical therapy. The two SNPs in GSTP1 and five SNPs
in EPHX1 that were significant in all LVRS patients were
tested for association. None of these genotype-phenotype
associations were significant in subjects from the medical
arm. Despite the smaller sample size in the medical arm,
power was reasonable to detect significant genetic associ-
ations. For GSTP1 SNP rs612020, the medical arm had
93% power to detect a similar effect on BODE score as was
seen in the LVRS patients. For EPHX1 SNPs rs3753658
and rs2234922 (His139Arg), power was 97% and 78%,
respectively, for the analyses of BODE in the medical arm.
Discussion
In participants from the NETT Genetics Ancillary Study,
we tested associations between variants in five candidate
genes and four measures of response to LVRS, finding sig-
nificant associations for SNPs in two genes, GSTP1 and
EPHX1. The effects of a SNP upstream from GSTP1 and a
coding SNP in EPHX1  were strongest in the clinically
defined subgroup of patients with non-upper lobe pre-
dominant emphysema and low baseline exercise toler-
ance. Additional SNPs in these two genes, including a
promoter SNP in EPHX1, appeared to have stronger
Table 3: Analysis of SNPs in GSTP1 in all subjects (significant at p < 0.05) and in 4 subgroups defined by NETT based on upper lobe 
predominant emphysema on chest CT (upper lobe predominant vs. non-upper lobe predominant) and baseline exercise capacity (low 
vs. high). Subgroups with p-value <0.1 are shown
SNP LVRS Response 
Phenotype
All subjects
(n = 203)
Upper lobe, low 
exercise
(n = 59)
Upper lobe, high 
exercise
(n = 84)
Non-upper lobe, low 
exercise
(n = 23)
Non-upper lobe, 
high exercise
(n = 37)
β p β p β p β p β p
rs612020 BODE -1.0 0.003 -1.5 0.03 -2.2 0.003
rs11227884 Post-BD FEV1, liters 0.15 0.003
Max work, watts 6.2 0.02 8.5 0.06
SNP = single nucleotide polymorphism; LVRS = lung volume reduction surgery; BODE = Body mass index, airflow Obstruction, Dyspnea, Exercise 
tolerance; BD = bronchodilator; FEV1 = forced expiratory volume in 1 second
Effect of GSTP1 rs612020 polymorphism in patient subgroups  defined by emphysema distribution and baseline exercise  capacity Figure 2
Effect of GSTP1 rs612020 polymorphism in patient subgroups 
defined by emphysema distribution and baseline exercise 
capacity. Six month change in BODE score is shown. The 
grey box represents the interquartile range, and the black 
line marks the median. One individual with T/T genotype has 
been removed for clarity of presentation.
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effects in patients with upper lobe predominant emphy-
sema and low baseline exercise tolerance.
Analysis of the NETT data has demonstrated that non-
high risk patients in the upper lobe predominant, low
baseline exercise capacity subgroup are most likely to ben-
efit from LVRS, with a survival advantage compared to
medical therapy [1]. Based on these results and previous
studies of LVRS [21], LVRS is widely accepted for patients
with severe airflow obstruction due to upper lobe pre-
dominant emphysema. Our findings in the upper lobe
predominant, low exercise capacity subgroup may distin-
guish a subset of these patients most likely to respond to
surgery. However, the role of LVRS for non-upper lobe
predominant emphysema is much less clear [16]. NETT
found no survival improvement from LVRS in the non-
upper lobe predominant, low baseline exercise capacity
subgroup, but did show the potential for symptomatic
benefit in these patients [1]. The genetic associations in
this subgroup may possibly identify patients with non-
upper lobe predominant emphysema who have the
potential to benefit from LVRS. However, the number of
patients included in this subgroup was small.
In contrast to traditional pharmacogenetic studies of
drugs and their metabolizing enzymes, the potential effect
of SNPs in GSTP1 and EPHX1, two genes encoding xeno-
biotic metabolizing enzymes, on the response to LVRS is
not obvious. Variants in these genes may influence an
individual's response to the inflammation produced by
surgery or to the oxidative stress resulting from single lung
ventilation during lung resection [22]. Alternatively, these
genetic variants may be identifying patients with different
subtypes of emphysema, beyond the subgroups defined
by radiographic distribution and baseline exercise capac-
ity. The fact that we could not replicate these associations
in patients randomized to medical therapy demonstrates
that the effects of these SNPs are not explained by genetic
influences on the natural history of emphysema with
severe airflow obstruction. The effects of variants in
Effect of EPHX1 rs3753658 promoter polymorphism in  patient subgroups defined by emphysema distribution and  baseline exercise capacity Figure 3
Effect of EPHX1 rs3753658 promoter polymorphism in 
patient subgroups defined by emphysema distribution and 
baseline exercise capacity. Six month change in BODE score 
is shown. The grey box represents the interquartile range, 
and the black line marks the median. Three individuals with 
T/T genotype have been removed for clarity of presentation.
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Table 4: Analysis of SNPs in EPHX1 in all lung volume reduction surgery subjects (significant at p < 0.05) and in 4 subgroups defined by 
NETT based on upper lobe predominant emphysema on chest CT (upper lobe predominant vs. non-upper lobe predominant) and 
baseline exercise capacity (low vs. high). Subgroups with p-value <0.1 are shown
SNP LVRS Response 
Phenotype
All subjects
(n = 203)
Upper lobe, low 
exercise
(n = 59)
Upper lobe, 
high 
exercise
(n = 84)
Non-upper lobe, low 
exercise
(n = 23)
Non-upper lobe, high 
exercise
(n = 37)
β p β p β p β p β p
rs3753658 BODE -0.8 0.008 -1.3 0.01
UCSD SOBQ -7.7 0.02 -11.7 0.05
rs1877724 Post-BD FEV1, 
liters
-0.06 0.04 -0.13 0.01
rs2234922 BODE 0.5 0.02 1.6 0.02
Max work, watts -3.7 0.05
rs1051741 Max work, watts -5.9 0.01 -8.4 0.09 -10.2 0.09
rs2292558 Max work, watts -5.1 0.03 -8.4 0.09 -10.2 0.09
SNP = single nucleotide polymorphism; LVRS = lung volume reduction surgery; BODE = Body mass index, airflow Obstruction, Dyspnea, Exercise 
tolerance; BD = bronchodilator; FEV1 = forced expiratory volume in 1 second; UCSD SOBQ = University of California, San Diego shortness of 
breath questionnaire (higher scores indicate more severe dyspnea)Respiratory Research 2007, 8:59 http://respiratory-research.com/content/8/1/59
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EPHX1 may be at least partially mediated through effects
on the post-operative course, including complications,
evidenced by the change in effect estimates in the analyses
excluding patients with post-LVRS hospital stays greater
than thirty days. It is unlikely that the associated SNPs are
exerting their effects through comorbid illnesses, since the
number of major comorbidities in NETT subjects was low
due to the study exclusion criteria [23].
One must also consider the potential effects of the specific
SNPs that we have determined to be significantly associ-
ated with LVRS outcome. A coding variant in GSTP1
(Ile105Val) has been associated with COPD and related
traits in several studies [24,25], but the results have not
been consistently replicated [5,26]. The SNP with the
strongest association in our study, rs612020, is located
upstream from the transcription start site of the GSTP1
gene. The functional effect of this particular SNP is not
clear, yet it is in complete LD (in European-Americans
from the HapMap project) with another upstream SNP,
rs7927381 (which was not genotyped in our study),
which may alter a putative CCAAT/enhancer-binding pro-
tein (CEBP) site. The transcription factor CEBP-γ may be
an important regulator of GSTP1 expression in human
bronchial epithelial cells [27].
In EPHX1, rs3753658 is in the promoter region, 290 bp
upstream from the transcription start site. The SNP is in
complete LD with another promoter SNP (rs3753660, not
genotyped in our study) [28], which may affect a binding
site for peroxisome proliferator-activated receptor-γ, a
modulator of airway inflammation in COPD [29]. SNP
rs2234922 is located in exon 4 and leads to an amino acid
change (His139Arg). Enzymes carrying this variation may
have increased activity [30]; this variant has been termed
the "fast" allele. Several studies have reported association
between another coding variant (Tyr113His, "slow"
allele) and COPD [31,32]. As with GSTP1, this finding has
not been consistently replicated. We have previously
reported a protective effect of the His139Arg variant on
COPD risk, comparing patients from NETT with control
subjects [5]; however, this association was not found in a
family-based study of COPD.
The published studies of GSTP1 and EPHX1 above have
largely examined associations with COPD susceptibility.
The present study is the first association analysis examin-
ing genetic influences on the response to a specific therapy
for COPD or emphysema. In a study of outcomes from
thoracic surgery, Shaw and colleagues genotyped six poly-
morphisms in five genes, finding associations for SNPs in
tumor necrosis factor (TNF) and interleukin-6 (IL6) with
the risk of complications in 155 patients undergoing lung
resections for cancer [33]. On average, their patients had
relatively preserved baseline pulmonary function. In addi-
tion, multiple studies have examined genetic and genomic
factors influencing outcomes from cardiac surgery [34].
Our study has several limitations. In NETT, DNA samples
were collected at various times following enrollment, and
not prior to randomization. Because subjects were
recruited into the NETT Genetics Ancillary Study after
enrollment into NETT, we could not examine whether
genetic variants influenced survival post-LVRS, since
patients who died soon after enrollment (e.g. peri-opera-
tive deaths) would not be included in the study.
In our analyses of four phenotypes and five genes, includ-
ing multiple SNPs in those genes, it is possible that the
positive results represent spurious associations due to the
multiple tests performed. Using a more stringent p-value
of 0.01, only three of the genotype-phenotype associa-
tions in our study (two SNPs in GSTP1 and one in EPHX1)
remained significant. In the complex trait genetics litera-
ture, there is no clear consensus regarding the optimal sta-
tistical methodology to control for multiple testing [35].
Increasingly, replication of the findings in an independent
population has emerged as the standard for confirming a
true genetic association [36]. A limitation of our study is
the lack of a suitable replication population. Other clini-
cal trials of LVRS [21] would likely be underpowered for
an adequate replication study, even if DNA were collected
on all subjects in these studies. For example, in the com-
bined analysis of the Canadian Lung Volume Reduction
Study and the Overholt-Blue Cross Emphysema Surgery
Trial, one of the largest LVRS trials outside of NETT, only
58 patients were randomized to surgery [37]. For a repli-
cation study, ideally one targets a sample size at least as
large as in the original study [38].
Conclusion
In the NETT Genetics Ancillary Study, we were able to
identify variants in two genes, GSTP1 and EPHX1, which
may predict outcome from LVRS, even when accounting
for clinically-defined subgroups based on radiographic
emphysema distribution and baseline exercise capacity.
This represents the first genetic association for response to
a specific therapy for COPD. Given that an adequate clin-
ical trial population for replication is unlikely to become
available, alternative methodologies must be employed to
validate our findings and to confirm their eventual clini-
cal relevance.
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